Protection 50 Sport

Homosalate, Octocrylene, Octisalate, And Avobenzone


Dermalogica, Llc.
Human Otc Drug
NDC 68479-232
Protection 50 Sport also known as Homosalate, Octocrylene, Octisalate, And Avobenzone is a human otc drug labeled by 'Dermalogica, Llc.'. National Drug Code (NDC) number for Protection 50 Sport is 68479-232. This drug is available in dosage form of Lotion. The names of the active, medicinal ingredients in Protection 50 Sport drug includes Avobenzone - 3 mg/100mL Homosalate - 10 mg/100mL Octisalate - 5 mg/100mL Octocrylene - 10 mg/100mL . The currest status of Protection 50 Sport drug is Active.

Drug Information:

Drug NDC: 68479-232
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Protection 50 Sport
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Homosalate, Octocrylene, Octisalate, And Avobenzone
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Dermalogica, Llc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Lotion
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:AVOBENZONE - 3 mg/100mL
HOMOSALATE - 10 mg/100mL
OCTISALATE - 5 mg/100mL
OCTOCRYLENE - 10 mg/100mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 05 Aug, 2019
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 25 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part352
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Dermalogica, LLC.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:G63QQF2NOX
V06SV4M95S
4X49Y0596W
5A68WGF6WM
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
68479-232-002 mL in 1 POUCH (68479-232-00)05 Aug, 2019N/ANo
68479-232-021 TUBE in 1 CARTON (68479-232-02) / 156 mL in 1 TUBE05 Aug, 2019N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose sunscreen

Product Elements:

Protection 50 sport homosalate, octocrylene, octisalate, and avobenzone homosalate homosalate octocrylene octocrylene octisalate octisalate avobenzone avobenzone water butylene glycol safflower oil dimethicone methyl methacrylate/glycol dimethacrylate crosspolymer c15-19 alkane vinylpyrrolidone/eicosene copolymer silicon dioxide dimethyl capramide polyglyceryl-2 stearate phenoxyethanol peg-100 stearate glyceryl stearate se arachidyl alcohol potassium cetyl phosphate squalane docosanol xanthan gum carbomer interpolymer type a (allyl sucrose crosslinked) arachidyl glucoside benzyl alcohol glycyrrhizinate dipotassium ethylhexylglycerin tetrasodium glutamate diacetate sodium hydroxide anhydrous citric acid

Indications and Usage:

Uses helps prevent sunburn. if used as directed with other sun protection measures (see directions ), helps decrease the risk of skin cancer and early skin aging caused by the sun.

Warnings:

Warnings for external use only. do not use on damaged or broken skin. when using this product keep out of eyes. rinse with water to remove. stop use and ask a doctor if rash occurs. keep out of reach of children. if swallowed, get medical help or contact a poison control center right away.

Do Not Use:

Warnings for external use only. do not use on damaged or broken skin. when using this product keep out of eyes. rinse with water to remove. stop use and ask a doctor if rash occurs. keep out of reach of children. if swallowed, get medical help or contact a poison control center right away.

When Using:

When using this product keep out of eyes. rinse with water to remove.

Dosage and Administration:

Directions apply liberally 15 minutes before sun exposure. reapply: - after 80 minutes of swimming or sweating. - immediately after towel drying. - at least every 2 hours. sun protection measures. spending time in the sun increases your risk of skin cancer and early skin aging. to help decrease this risk, regularly use a sunscreen with a broad spectrum spf of 15 or higher and other sun protection measures including: - limit time in the sun, especially from 10 a.m. – 2 p.m. - wear long-sleeve shirts, pants, hats and sunglasses. children under 6 months: ask a doctor.

Stop Use:

Stop use and ask a doctor if rash occurs.

Package Label Principal Display Panel:

Principal display panel - 156 ml tube carton protection 50 sport spf 50 broad spectrum 80 minutes water-resistant 5.3 us fl oz / 156 ml ℮ dermalogica principal display panel - 156 ml tube carton

Further Questions:

Questions or comments call toll free 1-800-831-5150 in the us


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.